GB1242211A - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
GB1242211A
GB1242211A GB3627067A GB3627067A GB1242211A GB 1242211 A GB1242211 A GB 1242211A GB 3627067 A GB3627067 A GB 3627067A GB 3627067 A GB3627067 A GB 3627067A GB 1242211 A GB1242211 A GB 1242211A
Authority
GB
Grant status
Application
Patent type
Prior art keywords
medicament
particle
composition
powder
size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3627067A
Inventor
Stephen Raymond Gunning
Philip Saxton Hartley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Pharmaceuticals Ltd
Original Assignee
Fisons Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/826Asthma

Abstract

1,242,211. Powder compositions for inhalation. FISONS PHARMACEUTICALS Ltd. 23 July, 1968 [8 Aug., 1967], No. 36270/67. Heading A5B. A pharmaceutical powder composition for inhalation comprises a mixture of a solid finely divided medicament having an effective particle size in the range 0.01 to 10 microns and a solid pharmaceutically acceptable water-soluble carrier having an effective particle size in the range 30-80 microns. The composition is preferably substantially free of particles having effective particle sizes in the range 11-29 microns. The medicament may be diluted with a solid pharmaceutically acceptable watersoluble diluent of the same effective particle size. The diluent or carrier may be dextran, mannitol or lactose preferably crystalline lactose. The medicament may be an antianaphylactic agent such as sodium chromoglycate, a sympathomimetic amine such as isoprenaline or ephedrine, an antibiotic such as penicillin or tetracycline, a steroid, enzyme, vitamin, antihistamine or mucolytic such as N- acetyl cysteine. A preferred composition contains sodium chromoglycate and isoprenaline sulphate. The surface characteristics of the medicament or carrier particles may have been modified by crystallisations, spray drying, precipitation or by coating with a pharmaceutically acceptable material, e.g. stearic acid or polyvinyl pyrrolidone (which coating may give the medicament sustained release action). The powder may be contained in a capsule, e.g. of gelatin or plastic, which is pierced for administration. The powder may be administered as a dispersion in an air stream obtained by simultaneous rotation and vibration of the pierced capsule. The composiitons are prepared by mixing together, preferably in a stirred mixer, the medicament and carrier, which if necessary have been subjected to comminution and particle size classification prior to mixing.
GB3627067A 1967-08-08 1967-08-08 Pharmaceutical composition Expired GB1242211A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB3627067A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB3627067A GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition
FI215868A FI48973C (en) 1967-08-08 1968-07-30 Process for the preparation of the inhaler is easily fluidized material.
BE718846A BE718846A (en) 1967-08-08 1968-07-31
US3634582A US3634582A (en) 1967-08-08 1968-07-31 Pharmaceutical compositions
CA 26437 CA946280A (en) 1967-08-08 1968-08-01 Inhalant powder compositions
NL6811060A NL161984C (en) 1967-08-08 1968-08-02 A process for the preparation of a pharmaceutical powdered inhaleerpreparaat, as well as container, which contains such a composition.
DE19681792799 DE1792799A1 (en) 1967-08-08 1968-08-03 pharmaceutical products
DE19681792207 DE1792207C3 (en) 1967-08-08 1968-08-03
DK380968A DK123276B (en) 1967-08-08 1968-08-07 A method of making a readily fluidisable inhalant.
FR8142M FR8142M (en) 1967-08-08 1968-08-07
FR163601A FR1605538A (en) 1967-08-08 1968-08-21
JP2321371A JPS5643448B1 (en) 1967-08-08 1971-04-14
US3860618A US3860618A (en) 1967-08-08 1971-06-29 Chromone
US05401251 US3957965A (en) 1967-08-08 1973-09-27 Sodium chromoglycate inhalation medicament

Publications (1)

Publication Number Publication Date
GB1242211A true true GB1242211A (en) 1971-08-11

Family

ID=10386572

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3627067A Expired GB1242211A (en) 1967-08-08 1967-08-08 Pharmaceutical composition

Country Status (10)

Country Link
US (1) US3634582A (en)
JP (1) JPS5643448B1 (en)
BE (1) BE718846A (en)
CA (1) CA946280A (en)
DE (2) DE1792207C3 (en)
DK (1) DK123276B (en)
FI (1) FI48973C (en)
FR (2) FR8142M (en)
GB (1) GB1242211A (en)
NL (1) NL161984C (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2229981A1 (en) * 1971-06-22 1972-12-28
FR2481601A1 (en) * 1980-04-30 1981-11-06 Fisons Ltd A pharmaceutical mixture of 1,3-bis- (2-carboxychromone-5-yl-oxy) -propan-2-ol, or a salt thereof, and at least one bronchodilator
US4515805A (en) * 1980-11-05 1985-05-07 Fisons Plc Soluble sodium cromoglycate compositions
US5551489A (en) * 1993-10-01 1996-09-03 Astra Aktiebolag Agglomeration of finely divided powders
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6153224A (en) * 1995-01-31 2000-11-28 Co-Ordinated Drug Development Limited Carrier particles for use in dry powder inhalers
US6183782B1 (en) 1994-03-15 2001-02-06 Glaxo Group Limited Inhalation composition containing lactose pellets
US6221338B1 (en) 1993-10-26 2001-04-24 Vectura Limited Method of producing particles for use in dry powder inhalers
US6371171B1 (en) 1993-10-01 2002-04-16 Astra Aktiebolag Agglomeration of finely divided powders
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6884794B2 (en) 2000-04-17 2005-04-26 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
US7399528B2 (en) 1999-07-16 2008-07-15 Chiesi Farmaceutici S.P.A. Powder particles with smooth surface for use in inhalation therapy
US7541022B2 (en) 2000-04-17 2009-06-02 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US8205614B2 (en) 1999-09-04 2012-06-26 Innovata Biomed Limited Delivery device
US8236979B2 (en) 2008-07-24 2012-08-07 American Air Liquide, Inc. Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
WO2013104892A1 (en) 2012-01-13 2013-07-18 Hovione Inter Limited Application of high dose compounds via inhalation
US8511302B2 (en) 2004-04-24 2013-08-20 Innovata Biomed Limited Dose counter mechanisms for medicament delivery devices
US8800550B2 (en) 2001-11-23 2014-08-12 Innovata Biomed Limited Medicament delivery assembly
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
US9987229B2 (en) 2003-09-02 2018-06-05 Norton Healthcare Ltd. Process for preparing a medicament

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787100A (en) * 1971-08-06 1973-02-02 Beecham Group Ltd A composition for the treatment of asthma
GB1410588A (en) * 1971-08-10 1975-10-22 Fisons Ltd Composition
DE2332663C2 (en) * 1973-06-23 1986-07-31 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De
DE2535258C2 (en) * 1974-08-10 1993-06-03 Fisons Plc, Ipswich, Suffolk, Gb
US4161516A (en) * 1975-07-25 1979-07-17 Fisons Limited Composition for treating airway disease
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
JPS6237016B2 (en) * 1983-03-09 1987-08-10 Teijin Ltd
US5204113A (en) * 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
DE3872635D1 (en) * 1987-04-09 1992-08-13 Fisons Plc Pentamidine pharmaceutical compositions containing them.
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalation powders and methods for their preparation
CA2115444C (en) * 1992-06-12 2000-10-03 Yuji Makino Preparation for intratracheobronchial administration
NL9301851A (en) * 1993-10-26 1995-05-16 Cordis Europ Cryo-ablation catheter.
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation
DE69825995D1 (en) * 1997-05-27 2004-10-07 Direct Haler As Odense An inhaler for powdered medications
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
ES2310047T3 (en) 1998-08-18 2008-12-16 The Regents Of The University Of California Antagonists epidermal growth factor receptor for the treatment of hypersecretion of mucus in the lungs.
EP1129705A1 (en) * 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
ES2259046T5 (en) 2000-10-12 2011-02-28 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Process for producing formulations in powder form.
CA2395653C (en) * 2000-10-12 2006-05-09 Boehringer Ingelheim Pharma Kg New inhalable powder containing tiotropium
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10141377A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Sprinkling method for preparation of powder formulations
JP2005507881A (en) * 2001-09-17 2005-03-24 グラクソ グループ リミテッドGlaxo Group Limited Dry powder pharmaceutical formulations
WO2003043574A3 (en) * 2001-11-19 2004-03-04 Becton Dickinson Co Pharmaceutical compositions in particulate form
US6900317B2 (en) * 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20040014679A1 (en) * 2002-02-20 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co., Kg Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
DE10207026A1 (en) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
JP2006516531A (en) * 2002-08-21 2006-07-06 ノートン ヘルスケアー リミテッドNorton Healthcare Ltd. Inhalation composition
DE10255387A1 (en) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg New tiotropium containing powder formulation for inhalation
DE10317461A1 (en) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
US20050042178A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
DE10338403A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulation containing the CGRP antagonist 1- [N2- [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxochinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, processes for its preparation and its use as Inhalativum
DE10338407A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg New Inhalation powder containing the CGRP antagonist 1- [N2- [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxochinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine
US20050042179A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
US20050043247A1 (en) * 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
DE10338402A1 (en) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried, amorphous BIBN 4096, process for its preparation and its use as Inhalativum
ES2390458T3 (en) 2003-11-04 2012-11-13 Glaxo Group Limited Muscarinic antagonists acetylcholine M3 receptor
CA2755954C (en) 2004-04-27 2014-02-18 Glaxo Group Limited Quaternary quinuclidine derivatives and their use as muscarinic receptor antagonists
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004048389A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modifying surfaces of lactose as an excipient for use in powdered inhalants
DE102004048390A1 (en) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg New inhalation powders based on modified lactose mixtures as an adjuvant
CN104177448A (en) * 2005-02-10 2014-12-03 葛兰素集团有限公司 Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007769A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and glucose anhydrous

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1489749A (en) * 1965-03-25 1967-07-28 Fisons Pharmaceuticals Ltd A process for preparing bis-chromonylés and their derivatives

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2229981A1 (en) * 1971-06-22 1972-12-28
FR2481601A1 (en) * 1980-04-30 1981-11-06 Fisons Ltd A pharmaceutical mixture of 1,3-bis- (2-carboxychromone-5-yl-oxy) -propan-2-ol, or a salt thereof, and at least one bronchodilator
US4515805A (en) * 1980-11-05 1985-05-07 Fisons Plc Soluble sodium cromoglycate compositions
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6371171B1 (en) 1993-10-01 2002-04-16 Astra Aktiebolag Agglomeration of finely divided powders
US5551489A (en) * 1993-10-01 1996-09-03 Astra Aktiebolag Agglomeration of finely divided powders
US6582678B2 (en) 1993-10-26 2003-06-24 Vectura Limited Carrier particles for use in dry powder inhalers
US6221338B1 (en) 1993-10-26 2001-04-24 Vectura Limited Method of producing particles for use in dry powder inhalers
US8137657B2 (en) 1993-10-26 2012-03-20 Vectura Limited Carrier particles for use in dry powder inhalers
US6955824B1 (en) 1994-03-15 2005-10-18 Glaxo Group Limited Inhalation composition containing lactose pellets
US6183782B1 (en) 1994-03-15 2001-02-06 Glaxo Group Limited Inhalation composition containing lactose pellets
US6102036A (en) * 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
EP2213279A3 (en) * 1995-01-31 2010-10-13 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
US7011818B2 (en) 1995-01-31 2006-03-14 Vectura Limited Carrier particles for use in dry powder inhalers
EP1666023A2 (en) 1995-01-31 2006-06-07 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
EP2258342A3 (en) * 1995-01-31 2014-01-08 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
US8920781B2 (en) 1995-01-31 2014-12-30 Vectura Limited Carrier particles for use in dry powder inhalers
US7718163B2 (en) 1995-01-31 2010-05-18 Vectura Limited (01696917) Carrier particles for use in dry powder inhalers
US6153224A (en) * 1995-01-31 2000-11-28 Co-Ordinated Drug Development Limited Carrier particles for use in dry powder inhalers
EP1666023B1 (en) * 1995-01-31 2011-10-05 Vectura Limited Improvements in and relating to carrier particles for use in dry powder inhalers
US7399528B2 (en) 1999-07-16 2008-07-15 Chiesi Farmaceutici S.P.A. Powder particles with smooth surface for use in inhalation therapy
US8205614B2 (en) 1999-09-04 2012-06-26 Innovata Biomed Limited Delivery device
EP2272508A2 (en) 2000-04-17 2011-01-12 Vectura Limited Pharmaceutical Formulations for Dry Powder Inhalers
US9566239B2 (en) 2000-04-17 2017-02-14 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US7541022B2 (en) 2000-04-17 2009-06-02 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US7223748B2 (en) 2000-04-17 2007-05-29 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
US8871274B2 (en) 2000-04-17 2014-10-28 Vectura Limited Pharmaceutical formulations for dry powder inhalers
US6884794B2 (en) 2000-04-17 2005-04-26 Chiesi Farmaceutici S.P.A. Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
EP1719505A2 (en) 2000-04-17 2006-11-08 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulations for dry powder inhalers in the form of hard pellets
US8800550B2 (en) 2001-11-23 2014-08-12 Innovata Biomed Limited Medicament delivery assembly
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US9987229B2 (en) 2003-09-02 2018-06-05 Norton Healthcare Ltd. Process for preparing a medicament
US8851069B2 (en) 2004-04-21 2014-10-07 Innovata Biomed Limited Inhaler
US8511302B2 (en) 2004-04-24 2013-08-20 Innovata Biomed Limited Dose counter mechanisms for medicament delivery devices
US8236979B2 (en) 2008-07-24 2012-08-07 American Air Liquide, Inc. Methods for synthesis of heteroleptic cyclopentadienyl transition metal precursors
WO2013104892A1 (en) 2012-01-13 2013-07-18 Hovione Inter Limited Application of high dose compounds via inhalation

Also Published As

Publication number Publication date Type
BE718846A (en) 1969-01-31 grant
FR8142M (en) 1970-08-17 grant
FI48973C (en) 1975-03-10 grant
DE1792799A1 (en) 1977-08-11 application
CA946280A (en) 1974-04-30 grant
FI48973B (en) 1974-12-02 application
CA946280A1 (en) grant
FR1605538A (en) 1979-02-23 grant
DE1792207A1 (en) 1971-11-04 application
DK123276B (en) 1972-06-05 grant
DE1792207B2 (en) 1977-10-13 application
NL161984B (en) 1979-11-15 application
US3634582A (en) 1972-01-11 grant
NL161984C (en) 1980-04-15 grant
NL6811060A (en) 1969-02-11 application
JPS5643448B1 (en) 1981-10-13 grant
DE1792207C3 (en) 1978-06-29 grant

Similar Documents

Publication Publication Date Title
US3445563A (en) Process of preparing vitamin-containing gelled aqueous colloid beads
US4837031A (en) Compositions containing ibuprofen
US3860733A (en) Microencapsulated product
US5382435A (en) Microparticulate pharmaceutical delivery system
Tabata et al. Synthesis of gelatin microspheres containing interferon
Pilcer et al. Formulation strategy and use of excipients in pulmonary drug delivery
US3148124A (en) Method of preparing sustained release pharmaceutical tablets
Louey et al. Particle interactions involved in aerosol dispersion of ternary interactive mixtures
US3932615A (en) Process for the preparation of granules
US4036948A (en) L-ascorbic acid tablets
US6541014B2 (en) Antiviral product, use and formulation thereof
US5824339A (en) Effervescent composition and its production
US6221393B1 (en) Pharmaceutical compositions in the form of sustained-release tablets based on high molecular weight polysaccharide granules
US6368625B1 (en) Orally disintegrable tablet forming a viscous slurry
US5955107A (en) Pharmaceutical suspension tablet compositions
US3887692A (en) Microspherical basic aluminum halides and method of making same
US5145683A (en) Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US6221392B1 (en) Rapidly dissolving robust dosage form
US5543099A (en) Process to manufacture micronized nifedipine granules for sustained release medicaments
US4835142A (en) Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
US6071497A (en) Microparticles for lung delivery comprising diketopiperazine
US5215755A (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
US4352789A (en) Aerosol compositions containing finely divided solid materials
US8568784B2 (en) Nanoparticles for delivery of active agents
US5863554A (en) Enhanced uptake drug delivery system